
Opinion|Videos|February 23, 2026
Final Perspectives on APP Contributions to Alzheimer Disease Care
Author(s)Ken Cohen, MD, FACP
Panelists discuss how APPs are essential leaders shaping the future of Alzheimer disease care.
Advertisement
Episodes in this series

Panelists discuss how the Alzheimer care landscape continues to evolve, positioning advanced practice providers (APPs) as central figures in its transformation. Their leadership spans early detection, therapy delivery, and caregiver support.
Panelists discuss how continuous education and collaboration will remain critical as new treatments and technologies emerge. The panel underscores the need for APP empowerment to maintain quality amid rapid scientific change.
Panelists discuss how their collective contributions redefine Alzheimer care as a collaborative, patient-focused endeavor grounded in accessibility, empathy, and innovation.
Advertisement
Related to this article

Among 821,327 outpatients, cystatin C–based eGFR at least 30% below creatinine-based eGFR was linked to higher death and heart failure rates.

Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.

The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.

In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.

Pharmacy teams can shorten the time of Medicare GLP-1 Bridge approvals, but 2027 approval windows may leave patients without titration check-ins.

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.
Advertisement
Advertisement
Trending on AJMC
1
Complicated UTI Care Strained by Unclear Goals, Access Gaps
2
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
3
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
4
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
5

